Overview

Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)

Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The aim ist to identify biomarkers in the blood, to indicate early response or early treatment resistance.
Phase:
Phase 2
Details
Lead Sponsor:
Association of Urogenital Oncology (AUO)
Association of Urologic Oncology (AUO)
Collaborator:
University Hospital, Essen
Treatments:
Sunitinib